Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (141-150 of 180) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|May 13, 1999
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsW C Zamboni, L C Bowman, M Tan, et al.
Journal of Clinical Pharmacology|January 15, 2011
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Journal of Liposome Research|June 10, 2010
Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor modelsWilliam C Zamboni, Julie L Eiseman, Sandra Strychor, et al.
International Journal of Nanomedicine|November 1, 2012
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2011
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticlesTimothy J Merkel, Stephen W Jones, Kevin P Herlihy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2000
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumorsW C Zamboni, M J Egorin, D A Van Echo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatinWilliam C Zamboni, Anne C Gervais, Merrill J Egorin, et al.
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Journal of Liposome Research|July 15, 2010
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsWilliam C Zamboni, Lauren J Maruca, Sandra Strychor, et al.
Cancer Investigation|January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
Pageof 18

Showing results (141-150 of 180) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|May 13, 1999
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsW C Zamboni, L C Bowman, M Tan, et al.
Journal of Clinical Pharmacology|January 15, 2011
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Journal of Liposome Research|June 10, 2010
Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor modelsWilliam C Zamboni, Julie L Eiseman, Sandra Strychor, et al.
International Journal of Nanomedicine|November 1, 2012
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2011
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticlesTimothy J Merkel, Stephen W Jones, Kevin P Herlihy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2000
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumorsW C Zamboni, M J Egorin, D A Van Echo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatinWilliam C Zamboni, Anne C Gervais, Merrill J Egorin, et al.
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Journal of Liposome Research|July 15, 2010
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsWilliam C Zamboni, Lauren J Maruca, Sandra Strychor, et al.
Cancer Investigation|January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
Pageof 18